Upcoming earnings set the tone for Ardent Health stock

Ardent Health (ARDT) is back in focus as investors weigh expectations for its June 2026 quarter. Forecasts point to lower revenue and earnings, yet models still point to a possible upside EPS surprise.

The share price of Ardent Health has pulled back 4.7% over the last day. However, the 30 day share price return of 10.1% and year to date share price return of 26.5% point to building momentum despite a modest 2.3% total shareholder return over one year.

If the upcoming earnings update has you reassessing opportunities in healthcare, it can help to widen the search and review 41 healthcare AI stocks.

After Ardent Health’s quick pullback, the stock still sits below average analyst price targets, while one valuation model suggests it might already exceed intrinsic value. Where does fair value really sit in that spread?

Most Popular Narrative: 12.6% Undervalued

The most followed narrative on Ardent Health pegs fair value at $12.50 per share, above the last close at $10.93. This sets up a clear valuation gap tied to long term earnings and margin assumptions.

The analysts have a consensus price target of $12.5 for Ardent Health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $10.0.

Curious what sits behind that spread in targets. The narrative leans on steady revenue expansion, firmer margins, and a future earnings multiple that could reset how Ardent Health is priced.

Result: Fair Value of $12.50 (UNDERVALUED)

However, Ardent Health still faces meaningful risks, including possible Medicaid funding changes and ongoing payer denial disputes that could pressure revenue and margins if conditions were to worsen.

Another View on Ardent Health’s Valuation

The earlier narrative leans on analyst targets that suggest Ardent Health is undervalued. The SWS DCF model points in the opposite direction. It places fair value at $1.95 per share, which is well below the current $10.93 price and implies the stock looks expensive on that framework.

Our DCF model is only as useful as its assumptions. It is worth checking how sensitive that $1.95 figure is to different growth or discount rate views before leaning on it too heavily, or ignoring it outright.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ardent Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on Ardent Health so far, this is a moment to move quickly and review the core data yourself to decide what really stands out. To weigh both sides in one place, take a look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ardent Health?

If Ardent Health has your attention, do not stop there. Use the Simply Wall St stock screener to uncover other opportunities before the market focuses on them.

• Spot potential value early by hunting for companies that still look attractively priced using the 49 high quality undervalued stocks.
• Strengthen your income focus by checking out stocks that combine higher yields with resilience through the 9 dividend fortresses.
• Prioritise resilience by filtering for companies with lower risk profiles and steadier characteristics via the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.